2024-11-15T02:30:30-06:00 2023-12-31 221478099 COHNREZNICK LLP 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2023-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQ 5714831700 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 MELINDA O'LEARY CFO 5714831700 2024-11-14 1 1 LORI ROTHE YOKOBOSKY CPA P01273422 3016529100 2024-11-13 2023 2024-10-15 13:58:12Z CONQUER CANCER & CONQUER CANCER FDTN NANCY DALY MS MPH 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 45995246 0 X WWW.CONQUER.ORG X 1999 VA TO ACCELERATE BREAKTHROUGHS IN LIFESAVING RESEARCH AND EMPOWER PEOPLE EVERYWHERE TO CONQUER CANCER. 21 20 0 300 0 0 31125188 34540916 363476 1328134 1837688 3429291 -192660 -201634 33133692 39096707 20648632 19433873 0 0 0 0 257693 358751 7307153 11982603 13783056 32888928 33575680 244764 5521027 98117170 110051603 14432042 13025732 83685128 97025871 X CONQUER CANCER FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. WORKING IN COLLABORATION WITH A GLOBAL NETWORK OF TOP SCIENTISTS AND CLINICIANS, AND LEADING ADVOCACY AND RESEARCH ORGANIZATIONS, CONQUER CANCER DRAWS (CONTINUED IN SCHEDULE O) ON THE PASSION AND EXPERTISE OF THE CANCER PROFESSIONALS WHO ARE MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). CONQUER CANCER WORKS TO HELP CREATE A WORLD WHERE CANCER IS PREVENTED OR CURED AND EVERY SURVIVOR IS HEALTHY. 0 0 16665053 12041145 SEE SCHEDULE O:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $190 MILLION TO SUPPORT GRANTS & AWARDS TO OVER 9,200 RECIPIENTS IN 89 COUNTRIES.HIGHLIGHTS OF 2023 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $1,350,000 PROVIDED THREE (3) THREE-YEAR AWARDS TO SUPPORT PHYSICIAN-SCIENTISTS COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. TWO AWARDS SUPPORTED DIVERSITY/INCLUSION, FOCUSING ON BREAST CANCER AND ONE AWARD FOCUSED ON TRIPLE-NEGATIVE BREAST CANCER.*CAREER DEVELOPMENT AWARD (CDA): $4,200,000 PROVIDED TWENTY-ONE (21) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS.*YOUNG INVESTIGATOR AWARD (YIA): $4,550,000 PROVIDED NINETY-ONE (91) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT.*GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $250,000 PROVIDED FIVE (5) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS.THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR.*INTERNATIONAL INNOVATION GRANT: $100,000 PROVIDED FIVE (5) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES OUR SKILLS AND EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE. 6151814 5955643 SEE SCHEDULE O:PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2023 INCLUDE THE FOLLOWING:* ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY WITH MORE THAN 44,000 PARTICIPANTS WORLDWIDE IN 2023. THE ANNUAL MEETING PROVIDES A FORUM TO JOIN GLOBAL CANCER EXPERTS AND DISCOVER THE LATEST INNOVATIONS IN CANCER RESEARCH AND EDUCATION WHILE ADDRESSING THE NEED FOR EVERY PATIENT TO RECEIVE THE HIGHEST QUALITY AND EQUITABLE CANCER CARE AVAILABLE.*GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS.*GENITOURINARY CANCERS (GU) SYMPOSIUM: THIS IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS.*QUALITY CARE SYMPOSIUM: THIS IS AN UNPARALLELED OPPORTUNITY TO LEVERAGE THE MOST UP-TO-DATE SCIENCE AND DISCOVER PROVEN STRATEGIES AND TOOLS CRITICAL TO MAKING KEY DECISIONS THAT CAN REDUCE DISPARITIES IN CARE FOR EVERY PATIENT, EVERY DAY, EVERYWHERE.*MERIT AWARDS: $304,000 PROVIDED TWO HUNDRED NINETY-NINE (299) MERIT AWARDS PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA.*MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR): $212,500 PROVIDED TWENTY-FIVE (25) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER. 1456370 1437086 1328134 SEE SCHEDULE O:QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED.THROUGHOUT ASCO AND CONQUER CANCER'S HISTORY, THE ORGANIZATIONS HAVE STRIVED TO IMPROVE CARE FOR ALL PATIENTS WITH CANCER WHILE PAYING PARTICULAR ATTENTION TO THOSE MOST VULNERABLE. IN 2023, ASCO AND CONQUER CANCER CONTINUED WORK ON QUALITY AND EQUITABLE ACCESS TO CARE PROGRAMS THROUGH THEIR EQUITY, DIVERSITY AND INCLUSION INITIATIVE: ASCO AND CONQUER CANCER'S EQUITY, DIVERSITY AND INCLUSION INITIATIVE IS AMBITIOUS YET REALISTIC AND AIMS TO ADDRESS DISPARITIES AND WORK TOWARD ACHIEVING GREATER EQUITY IN CANCER CARE. PROGRAMS UNDER THIS INITIATIVE ADDRESS SUCH AREAS AS EDUCATION AND DIVERSIFICATION OF THE ONCOLOGY WORKFORCE AND SUPPORT FOR ONCOLOGISTS AND TRAINEES FROM UNDERREPRESENTED POPULATIONS IN MEDICINE; INCREASING PARTICIPATION BY DIVERSE POPULATIONS IN CLINICAL TRIALS; RESEARCH GRANTS IN DIVERSITY, INCLUSION, AND HEALTH DISPARITIES; PROVIDER TRAINING TO ADDRESS GAPS IN HEALTH DISPARITIES AND INCLUSION; AND ADDRESSING THE SPECIALIZED NEEDS OF POPULATIONS IN RURAL AREAS OF THE US. 24273237 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 1 282 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 21 20 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 0 0 0 AL AR CA CT FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY ND OR PA RI SC TN UT VI WV WI X X MELINDA O'LEARY 5714831300 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 CLIFFORD A HUDIS MD EXECUTIVE VICE CHAIR 6.50 31.00 X X 0 1060801 24750 HOWARD A BURRIS III MD BOARD CHAIR 1.00 2.00 X X 0 0 0 AMY C PETERSON MD SECRETARY 1.00 X X 0 0 0 ALEXANDER W CASDIN TREASURER 1.00 X X 0 0 0 KATHRYN BEAL BOARD MEMBER 1.00 X 0 0 0 WILLIAM BEHNKE BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 RICCARDO BRAGLIA BOARD MEMBER 1.00 X 0 0 0 OTIS BRAWLEY MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 LAWRENCE H EINHORN MD BOARD MEMBER 1.00 X 0 0 0 RAJ MANTENA RPH BOARD MEMBER 1.00 X 0 0 0 THOMAS A MARSLAND MD BOARD MEMBER 1.00 X 0 0 0 ROBERT J MAYER MD BOARD MEMBER 1.00 X 0 0 0 GERALD J MCDOUGALL BOARD MEMBER 1.00 X 0 0 0 ANNE MOORE MD BOARD MEMBER 1.00 X 0 0 0 W CHARLES PENLEY MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 THOMAS G ROBERTS JR MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 STEVEN T ROSEN MD BOARD MEMBER 1.00 X 0 0 0 ALEXANDRA SHAPIRO BOARD MEMBER 1.00 X 0 0 0 SANDRA SWAIN MD BOARD MEMBER 1.00 X 0 0 0 MARGARET A TEMPERO MD BOARD MEMBER 1.00 X 0 0 0 DEANNA B VAN GESTEL BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 LINDA JENSEN CFO & EXECUTIVE VP 1.00 36.50 X 0 477532 42792 NANCY DALY MS MPH CEO & EXECUTIVE VP 36.50 1.00 X 0 516637 42677 0 2054970 110219 0 0 1 0 TRUE NORTH INC 12 WEST 27TH STREET 13TH FLOOR NEW YORK NY 10001 PRO FUNDRAISING SERVICES 168000 THE HARRINGTON AGENCY 329 DICKINSON AVENUE SWARTHMORE PA 19081 PRO FUNDRAISING SERVICES 127500 2 2923 1136500 2533767 3652500 678681 26536545 459764 34540916 GRANTS EXPERTISE 900099 1328134 1328134 1328134 2573994 2573994 7552202 6696905 855297 855297 855297 0 2533767 201634 -201634 -201634 39096707 1328134 0 3227657 18223892 18223892 393000 393000 816981 816981 8910924 2888058 1453334 4569532 45600 45600 358751 358751 52202 52202 1901034 1200128 218668 482238 88750 88750 1142478 133119 92442 916917 819814 128249 94160 597405 158678 158550 128 531135 324014 38756 168365 132441 7246 125195 33575680 24273237 1995290 7307153 9023972 5985305 5402813 10280846 25000 130103 85000 83560282 93675452 98117170 110051603 160281 186512 8376287 6724249 3179628 3440100 2715846 2674871 14432042 13025732 X 34722323 37868738 48962805 59157133 83685128 97025871 98117170 110051603 5521027 7819716 0 X X 0 1 X 1 0 X 27209762 34795083 22059688 31125188 34540916 149730637 27209762 34795083 22059688 31125188 34540916 149730637 29688773 120041864 2667684 1592952 1980450 1978770 2573994 10793850 269300 276883 546183 106173 106173 161176843 2154069 0.74480 0.81660 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 35282081 6649346 4658864 1470639 45119652 39078370 2822771 -5342139 1276921 35282081 35692561 1997125 2783059 1394375 39078370 27740161 6504115 2786765 1338480 35692561 17571755 8235901 2772005 839500 27740161 0.00000 1.00000 0.00000 0 0 0 DUE TO ASCO 2674871 2674871 X 47065855 7819716 7819716 39246139 52202 -201634 -149432 39096707 33725112 201634 201634 33523478 52202 52202 33575680 PART V, LINE 4: PERMANENTLY RESTRICTED NET ASSETS OF DONOR-RESTRICTED ENDOWMENT FUNDS ARE PRESERVED, ABSENT EXPLICIT DIRECTION FROM THE DONOR. INTEREST FROM THE PERMANENTLY RESTRICTED FUNDS IS INTENDED TO FUND FUTURE RESEARCH AND/OR EDUCATIONAL AWARDS. PART X, LINE 2: CONQUER CANCER IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("IRC"). IT HAS BEEN GRANTED PUBLIC CHARITY STATUS BY THE INTERNAL REVENUE SERVICE (THE "IRS") AND HAS BEEN CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. IN 2023 AND 2022, CONQUER CANCER GENERATED NO UNRELATED BUSINESS INCOME AND ACCORDINGLY HAD RELATED BUSINESS INCOME TAX OF $0 IN 2023 AND 2022, RESPECTIVELY. CONQUER CANCER ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). CONQUER CANCER BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, CONQUER CANCER IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2020. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE -201,634. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE 201,634. PART XII, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE PART V, LINES 1A-AG ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES AWARDS & GRANTS 250000 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 190000 SOUTH ASIA 0 0 PROGRAM SERVICES AWARDS & GRANTS 96981 NORTH AMERICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 190000 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES AWARDS & GRANTS 87000 0 0 0 0 0 0 813981 0 813981 SOUTH ASIA INTERNATIONAL INNOVATION GRANT (IIG) 19981 WIRE 0 SOUTH ASIA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD (GO YIA) 50000 WIRE 0 SUB-SAHARAN AFRICA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD (GO YIA) 50000 WIRE 0 SOUTH ASIA INTERNATIONAL INNOVATION GRANT (IIG) 20000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR AWARD (YIA), CAREER PATHWAY GRANT IN SYMPTOM MANAGEMENT 165000 WIRE 0 SUB-SAHARAN AFRICA INTERNATIONAL INNOVATION GRANT (IIG) 20000 WIRE 0 NORTH AMERICA INTERNATIONAL INNOVATION GRANT (IIG) 20000 WIRE 0 SUB-SAHARAN AFRICA GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD (GO YIA) 100000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR AWARD (YIA) 50000 WIRE 0 SUB-SAHARAN AFRICA INTERNATIONAL INNOVATION GRANT (IIG) 20000 WIRE 0 EAST ASIA AND THE PACIFIC YOUNG INVESTIGATOR AWARD (YIA) 50000 WIRE 0 NORTH AMERICA YOUNG INVESTIGATOR AWARD (YIA) 150000 WIRE 0 12 0 ANNUAL MEETING MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 20 20000 WIRE ANNUAL MEETING MERIT AWARD NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 10 10000 WIRE ANNUAL MEETING MERIT AWARD EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 3 3000 WIRE ANNUAL MEETING MERIT AWARD MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 1 1000 WIRE ANNUAL MEETING MERIT AWARD SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 2 2000 WIRE ANNUAL MEETING MERIT AWARD SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 1 1000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 2 2000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 4 4000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 2 2000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 3 3000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 6 6000 WIRE QUALITY CARE SYMPOSIUM MERIT AWARD EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 2 2000 WIRE QUALITY CARE SYMPOSIUM MERIT AWARD NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 2 2000 WIRE BREAKTHROUGH MERIT AWARD SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 2 2000 WIRE BREAKTHROUGH MERIT AWARD NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 3 3000 WIRE BREAKTHROUGH MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 2 2000 WIRE BREAKTHROUGH MERIT AWARD EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 5 5000 WIRE BREAKTHROUGH ABSTRACT AWARD EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 27 27000 WIRE BREAKTHROUGH ABSTRACT AWARD MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 1 1000 WIRE BREAKTHROUGH ABSTRACT AWARD SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 1 1000 WIRE BREAKTHROUGH ABSTRACT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 3 3000 WIRE 0 0 0 0 0 1 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL EARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. PART I, LINE 3: THE ACCRUAL METHOD IS USED TO ACCOUNT FOR FOREIGN EXPENDITURES. X X X X X X 1 TRUENORTH 515 MADISON AVE STE 8083 NEW YORK NY 10022 COUNSEL & MEDIA BUYS 0 462114 1107921 -645807 THE HARRINGTON AGENCY 329 DICKINSON AVENUE SWARTHMORE PA 19081 COUNSEL & MEDIA BUYS 0 276997 578944 -301947 FAIRCOM NEW YORK 12 WEST 27TH ST 13TH FLOOR NEW YORK NY 10001 DIRECT MAIL SOLICITATIONS 0 137895 216611 -78716 877006 1903476 -1026470 AL AK AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI INTEGRA CONNECT (OCTOBER) 1468251 1468251 CONQUER CANCER DINNER 674193 674193 86373 115261 9 391323 391323 2533767 2533767 86373 115261 201634 -201634 SCHEDULE G, PART I, LINE 2B, COLUMN (V) CONQUER CANCER PAYS A RETAINER FEE FOR FUNDRAISING SERVICES, INCLUDING STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. 1 CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD 65-WILS 1150 LOS ANGELES CA 90048 951644600 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA PA 19146 231352166 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD CITY OF HOPE 1500 E DUARTE ROAD DUARTE CA 91010 953435919 501(C)(3) 500000 0 ADVANCED CLINICAL RESEARCH AWARD, YOUNG INVESTIGATOR AWARD COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501(C)(3) 650000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 1700000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD, ADVANCED CLINICAL RESEARCH AWARD EMORY UNIVERSITY 1599 CLIFTON ROAD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD GEORGETOWN UNIVERSITY MEDICAL CENTER 37TH O STREETS NW WASHINGTON DC 20057 530196603 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE UNIVERSITY OF SOUTH FLOR 3702 SPECTRUM BLVD SUITE 165 TAMPA FL 33612 593102112 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD HENRY FORD HEALTH 2799 WEST GRAND BLVD DETROIT MI 482022689 381357020 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD JOHNS HOPKINS UNIVERSITY 733 N BROADWAY STE 117 BALTIMORE MD 21205 520595110 501(C)(3) 350000 0 YOUNG INVESTIGATOR AWARD MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 041564655 501(C)(3) 165000 0 CAREER PATHWAY GRANTS IN SYMPTOM MANAGEMENT, YOUNG INVESTIGATOR AWARD MAYO CLINIC ARIZONA 13400 E SHEA BOULEVARD SCOTTSDALE AZ 85259 860800150 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD MAYO CLINIC MINNESOTA 200 FIRST STREET SW ROCHESTER MN 559050001 416011702 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131624182 501(C)(3) 1500000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD NEW YORK UNIVERSITY (NYU) SCHOOL OF MEDICINE ONE PARK AVENUE 6TH FLOOR NEW YORK NY 10016 135562308 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DR RUBLOFF 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 165000 0 YOUNG INVESTIGATOR AWARD, LONG-TERM INTERNATIONAL FELLOWSHIP OHIO STATE UNIVERSITY 1960 KENNY RD COLUMBUS OH 43210 316025986 GOVT ENTITY 50000 0 YOUNG INVESTIGATOR AWARD SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 981053901 910564748 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD ST JUDE CHILDREN'S RESEARCH HOSPITAL INC 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501(C)(3) 50000 0 GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD STANFORD UNIVERSITY 455 BROADWAY ST REDWOOD CITY CA 940633126 941156365 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 770304009 760300816 501(C)(3) 950000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD THOMAS JEFFERSON UNIVERSITY 833 CHESTNUT STREET SUITE 900 PHILADELPHIA PA 19107 231352651 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVENUE SOUTH BIRMINGHAM AL 352940111 636005396 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 150000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF IOWA 100 GILMORE HALL IOWA CITY IA 52242 426004813 501(C)(3) 122000 0 CAREER PATHWAY GRANTS IN SYMPTOM MANAGEMENT UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE 1320 SOUTH DIXIE HWY CORAL GABLES FL 33146 590624458 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD UNIVERSITY OF NORTH CAROLINA CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CAMPUS BOX 1350 CHAPEL HILL NC 275991350 566001393 GOVT ENTITY 350000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR FRANKLIN BUILDING PHILADELPHIA PA 191046205 231352685 GOVT ENTITY 150000 0 YOUNG INVESTIGATOR AWARD, GIANNI BONADONNA BREAST CANCER RESEARCH FELLOWSHIP UNIVERSITY OF PITTSBURGH 300 MURDC 3420 FORBES AVENUE PITTSBURGH PA 15260 250965591 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET CUB 303 LOS ANGELES CA 90089 951642394 GOVT ENTITY 50000 0 YOUNG INVESTIGATOR AWARD UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 210 SALT LAKE CITY UT 841128906 876000525 501(C)(3) 200000 0 CAREER DEVELOPMENT AWARD UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE SEATTLE WA 981959472 916001537 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE SUITE 970 NASHVILLE TN 37203 352528741 501(C)(3) 50000 0 YOUNG INVESTIGATOR AWARD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 150000 0 YOUNG INVESTIGATOR AWARD YALE UNIVERSITY 25 SCIENCE PARK 3RD FLOOR NEW HAVEN CT 06511 060646973 501(C)(3) 150000 0 YOUNG INVESTIGATOR AWARD BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 021156110 042312909 501(C)(3) 250000 0 YOUNG INVESTIGATOR AWARD, CAREER DEVELOPMENT AWARD AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 136180380 501(C)(3) 7804140 0 CHARITABLE ASSISTANCE FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98391 911935159 501(C)(3) 100000 0 YOUNG INVESTIGATOR AWARD 39 0 MERIT AWARDS 185 188000 MEDICAL STUDENT ROTATION AWARDS 25 190000 ANNUAL MEETING RESEARCH AWARDS 10 15000 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES AND SPONSORING INSTITUTIONS ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CONQUER CANCER AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT BY THE END OF THE PROJECT PERIOD OR TO MEET THE PROPOSED TIME SCHEDULES. CONQUER CANCER MAY APPROVE UP TO A MAXIMUM OF THREE NO-COST EXTENSIONS OF SIX MONTH INCREMENTS. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE THEIR SPONSORING INSTITUTION DURING THE COURSE OF THEIR GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (EXPENDITURE REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND AN EXPENDITURE REPORT ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF EACH GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, A FINAL PROGRESS REPORT AND A FINAL EXPENDITURE REPORT ARE REQUIRED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CONQUER CANCER. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROGRESS REPORT, FINAL EXPENDITURE REPORT, ANY REMAINING BALANCE ON THE GRANT, AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS OF THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. 0 0 0 0 0 0 0 0 0 CLIFFORD A HUDIS MD EXECUTIVE VICE CHAIR 0 1049613 0 10000 0 1188 0 24750 0 0 0 1085551 0 0 NANCY DALY MS MPH CEO & EXECUTIVE VP 0 504351 0 10000 0 2286 0 24750 0 17927 0 559314 0 0 LINDA JENSEN CFO & EXECUTIVE VP 0 463824 0 10000 0 3708 0 24750 0 18042 0 520324 0 0 PART I, LINE 3 COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. (ASCO). THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 17 459764 FMV 0 0 1 0 PART I, COLUMN (B): THIS NUMBER REPRESENTS THE NUMBER OF CONTRIBUTIONS MADE, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 7A CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE TAX RETURN, INCLUDING ALL APPLICABLE SCHEDULES, WAS PROVIDED TO THE BOARD OF DIRECTORS, CHIEF FINANCIAL OFFICER AND GENERAL COUNSEL FOR REVIEW AND COMMENT PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE CHIEF EXECUTIVE OFFICER OF CONQUER CANCER, THE EXECUTIVE VICE CHAIR OF CONQUER CANCER, AND THE CHIEF FINANCIAL OFFICER OF CONQUER CANCER SERVE AS EMPLOYEES OF ASCO. INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION, INCLUDING REVIEW AND APPROVAL BY INDEPENDENT PERSONS, COMPARABILITY DATA, AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION, ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. PART XII, LINE 2C THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 136180380 EDUCATION NY 501(C)(3) LINE 10 N/A 0 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561639 MEMBER SERVICES VA 501(C)(6) ASCO 0 ASCO ASSOCIATION PAC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 PAC VA 527 ASCO ASSOCIATION 0 0 1 1 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 ASCO ASSOCIATION Q 89509 COST